Spring Innovation Week in Lisbon is approaching and we are thrilled to share that Biocytogen will be attending BIO-Europe Spring. Portugal’s healthcare industry is growing at a robust pace with health-related goods and services accounting for 5% of their total exports, and exceeding over €4 billion in 2024. This is the perfect time to join that momentum and help drive the next wave of innovation across the biotech and pharma landscape.
What is BIO-Europe Spring?
BIO-Europe Spring is Europe’s largest springtime biotech event, attracting 3,700+ global leaders and innovators from industry, academia, and finance, for three days of partnering, business development, and licensing opportunities across the life science sector. It will feature speaker sessions exploring key insights and latest trends, one-on-one networking meetings, and a full day of exhibitions.
Event Overview
Date: March 23rd - 25th, 2026
Venue: Feira Internacional de Lisboa, R. do Bojador, 1998-010 Lisboa, Portugal
Event Schedule
For more information, please refer to the event agenda.
About BIOCYTOGEN
Biocytogen (SSE: 688796; HKEX: 02315) is a global biotechnology company that drives the research and development of novel antibody-based drugs with innovative technologies. Founded on gene editing technology, Biocytogen leverages genetically engineered proprietary RenMice® platforms for fully human monoclonal/bispecific/multispecific antibody discovery, bispecific antibody-drug conjugate discovery, nanobody discovery and TCR mimic antibody discovery, and has established a sub-brand, RenBiologics™, to explore global partnerships for an off-the-shelf library of >1,000,000 fully human antibody sequences against over 1000 targets for worldwide collaboration. As of June 30, 2025, approximately 280 therapeutic antibody and multiple clinical asset co-development/out-licensing/transfer agreements and over 50 target-nominated RenMice® licensing projects have been established around the globe, including several partnerships with multinational pharmaceutical companies (MNCs). Biocytogen pioneered the generation of drug target knock-in humanized models for preclinical research, and currently provides a few thousand off-the-shelf animal and cell models under the company's sub-brand, BioMice™, along with preclinical pharmacology and gene-editing services for clients worldwide. Headquartered in Beijing, Biocytogen has branches in China (Haimen Jiangsu, Shanghai), USA (Boston, San Francisco, San Diego), and Germany (Heidelberg). For more information, please visit https://biocytogen.com.
Let’s drive the next generation of biotech innovation in Europe, see you in Lisbon, Portugal!
